Projected Long-Term Cost Savings with Roxadustat, a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI), among Patients on Hemodialysis: Insights from a 100-Week Longitudinal Study

Authors: Satoshi Funakoshi, Jyunichiro Hashiguchi, Shinichi Abe, Kenji Sawase, Mayu Iwata

Published: 2024-10-28

DOI: 10.1681/asn.20247rqnjvm7

Keywords: No keywords found.

Abstract:
No abstract found.

Source: